>
Switch to:

Amgen PB Ratio

: 14.35 (As of Today)
View and export this data going back to 1983. Start your Free Trial

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2021-10-25), Amgen's share price is $207.785. Amgen's Book Value per Share for the quarter that ended in Jun. 2021 was $14.48. Hence, Amgen's PB Ratio of today is 14.35.

The historical rank and industry rank for Amgen's PB Ratio or its related term are showing as below:

NAS:AMGN' s PB Ratio Range Over the Past 10 Years
Min: 1.8   Med: 4.18   Max: 17.18
Current: 14.39

1.8
17.18

During the past 13 years, Amgen's highest PB Ratio was 17.18. The lowest was 1.80. And the median was 4.18.

NAS:AMGN's PB Ratio is ranked lower than
61% of the 145 Companies
in the Drug Manufacturers industry.

( Industry Median: 3.87 vs. NAS:AMGN: 14.39 )

During the past 12 months, Amgen's average Book Value Per Share Growth Rate was -20.30% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -22.50% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -19.10% per year. During the past 10 years, the average Book Value Per Share Growth Rate was -3.60% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Amgen was 69.30% per year. The lowest was -27.30% per year. And the median was 16.45% per year.

Back to Basics: PB Ratio


Amgen PB Ratio Historical Data

The historical data trend for Amgen's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amgen Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
PB Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.61 4.98 9.81 14.74 14.13

Amgen Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
PB Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.98 13.53 14.13 15.33 16.83

Competitive Comparison

For the Drug Manufacturers - General subindustry, Amgen's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Amgen PB Ratio Distribution

For the Drug Manufacturers industry and Healthcare sector, Amgen's PB Ratio distribution charts can be found below:

* The bar in red indicates where Amgen's PB Ratio falls into.



Amgen PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Amgen's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Jun. 2021)
=207.785/14.479
=14.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Amgen  (NAS:AMGN) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Amgen PB Ratio Related Terms

Thank you for viewing the detailed overview of Amgen's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Amgen Business Description

Amgen logo
Industry
Healthcare » Drug Manufacturers NAICS : 325412 SIC : 2834
Address
One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Nexavar and Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), and Lumakras (lung cancer). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Executives
Sugar Ronald D director 10877 WILSHIRE BLVD. SUITE 1650 LOS ANGELES CA 900274
Williams R Sanders director DUKE UNIVERSITY SCHOOL OF MEDICINE TRENT DRIVE DURHAM NC 27706
Santos Esteban officer: EVP, Operations ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320
Miles Amy E director PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: MILES AMY E a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}
Kullman Ellen Jamison director UNITED TECHNOLOGIES CORP 10 FARM SPRINGS ROAD FARMINGTON CT 06032
Grygiel Nancy A. officer: SVP & CCO ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320
Louie Linda H. officer: VP, Finance & CAO ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320
Holley Charles M director PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: HOLLEY CHARLES M a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}
Griffith Peter H. officer: EVP & CFO ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320
Reese David M officer: EVP, Research and Development ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320
Druker Brian director ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320-1799
Austin Wanda M director 6001 BOLLINGER CANYON ROAD SAN RAMON CA 94583
Gordon Murdo officer: EVP Global Commercial Ops C/O BRISTOL-MYERS SQUIBB COMPANY 345 PARK AVE NEW YORK NY 10154
Piacquad David officer: SVP, Business Development ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320-1799
Patton Cynthia M officer: SVP & CCO ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320-1799

Amgen Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)